We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
30 Jan 2023 - 02 Feb 2023

CT Algorithm Diagnoses Clear-Cell Renal Cell Carcinoma in Small Solid Masses

By MedImaging International staff writers
Posted on 30 Jun 2022
Print article
Image: A 5-tiered CT scoring algorithm can diagnose clear-cell renal cell carcinoma in small solid masses (Photo courtesy of Pexels)
Image: A 5-tiered CT scoring algorithm can diagnose clear-cell renal cell carcinoma in small solid masses (Photo courtesy of Pexels)

A 5-tiered CT scoring algorithm may represent a clinically useful tool for diagnosis of clear-cell renal cell carcinoma (RCC) in small solid renal masses.

Researchers at The Ottawa Hospital (Ontario, Canada) conducted a study that included 148 patients (mean age, 58 years; 73 men, 75 women) with 148 small (≤4 cm) solid (>25% enhancing tissue) renal masses that underwent renal-mass CT (unenhanced, corticomedullary, and nephrographic phases) before resection between January 2016 and December 2019. Two radiologists independently evaluated the CT examinations and recorded calcification, mass attenuation in all phases, mass-to-cortex corticomedullary attenuation ratio, and heterogeneity score (5-point Likert scale, assessed in corticomedullary phase).

The study revealed that the 5-tiered CT scoring algorithm - including mass-to-cortex corticomedullary attenuation ratio and heterogeneity score - had substantial interobserver agreement (weighted kappa=0.71) and achieved AUC for diagnosing clear-cell RCC of 0.75 (95% CI, 0.68-0.82) for reader 1 and 0.72 (95% CI, 0.66-0.82) for reader 2.

“A 5-tiered renal CT algorithm, including mass-to-cortex corticomedullary attenuation ratio and heterogeneity score, had substantial inter-observer agreement, moderate AUC and PPV, and high NPV for diagnosing clear-cell RCC,” concluded Nicola Schieda from the department of medical imaging at Canada’s Ottawa Hospital.

“If validated,” the researchers acknowledged, “the CT algorithm may represent a useful clinical tool for diagnosing clear-cell renal cell carcinoma."

Related Links:
The Ottawa Hospital


Print article
CIRS -  MIRION
Radcal

Channels

MRI

view channel
Image: Hyperpolarized MRI technology reveals changes in heart muscle’s sugar metabolism after heart attack (Photo courtesy of ETH Zurich)

MRI Technology to Visualize Metabolic Processes in Real Time Could Improve Heart Disease Diagnosis

Magnetic resonance imaging (MRI) has become an indispensable part of medicine. It allows unique insights into the body and diagnosis of various diseases. However, current MRI technology has its limitations:... Read more

Ultrasound

view channel
Image: A combination of ultrasound and nanobubbles allows cancerous tumors to be destroyed without surgery (Photo courtesy of Tel Aviv University)

Ultrasound Combined With Nanobubbles Enables Removal of Tumors Without Surgery

The prevalent method of cancer treatment is surgical removal of the tumor, in combination with complementary treatments such as chemotherapy and immunotherapy. Therapeutic ultrasound to destroy the cancerous... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.